Year 2022, Volume 6 - Issue 3

Open access Case Report | April 10, 2022
Giant inflammatory myofibroblastic tumor of oral cavity: a case report and literature review
Demet Etit , Ardan Vergili , Muberra Konur , Mustafa Koray Balcı
Year: 2022 | Pages: 43 - 47
Background: Inflammatory myofibroblastic tumor is an infrequent lesion that is seen in the lungs, abdomen, skin, soft tissue, genital system, and mediastinum. It is rare in the oral cavity. Case presentation: A 58-year-old woman presented with a mass in the left buccal mucosa. An extensive surgical intervention was performed. On gross examination, the mass was 9.5 x 8 x 3.5 cm in size. Microscopically, the tumor included spindle-shaped myofibroblast-like cells intermingling chronic inflammatory cells. Differential diagnosis of inflammatory myofibroblastic tumor is extensive and includes benign and malignant spindle cell tumors, such as cranial fasciitis, solitary fibrous tumor, fibrosarcoma, and rhabdomyosarcoma. Conclusion: Inflammatory myofibroblastic tumors are classified as tumors of intermediate biological potential due to a tendency of local recurrence and low risk of distance metastasis. We found it appropriate to submit this case because of its rarity and rapid growth; also, it is the largest size oral cavity location inflammatory myofibroblastic tumor that has been reported so far.

Open access Case Report | April 12, 2022
Toxic pneumonitis induced by trastuzumab as a potentially fatal event: a case report
Raquel Fontes , Jorge Rodrigues , Camila Oliveira , Mauricio Peixoto , Ricardo Fernandes , Luisa Queiroz , Catarina Portela , Marta Almeida , Rui Nabico
Year: 2022 | Pages: 48 - 51
Background: Trastuzumab is a widely used and well-tolerated drug. Pulmonary toxicity has been described; however, the low incidence, the variability at presentation, and the nonspecific characteristics often make it an exclusion diagnosis. Case presentation: We present the case of a 62-year-old women admitted to our service with fever and shortness of breast after treatment with trastuzumab. From the study performed, no other cause was found to explain the event and the patient kept worsening until the diagnosis was established. Conclusion: Although pneumonitis is a rare side effect of trastuzumab administration, early recognition and appropriate therapy are crucial and may be lifesaving.

Open access Case Report | April 16, 2022
Missed diagnosis of oxalosis with disastrous consequences. Case reports of a father and daughter
Rui Nabico , Udayakumar Ramachandran , Usman Khan , Quratulain Sabih , Kashif Rahim , M. Babar Imran
Year: 2022 | Pages: 52 - 57
Background: Hyperoxalosis is a rare disease that originates from a defect in a liver enzyme and results in renal failure, if not diagnosed in time. Once end-stage renal disease is established, a transplant is the treatment of choice. But a kidney-only transplant can fail due to the mobilization of the excess oxalates in the tissue, and many authorities recommend a combined kidney-liver transplant. Case Presentation: We describe a case where the diagnosis of oxalosis was missed, resulting in renal transplant failure and excision of the graft. The diagnosis was made only on noting florid heterotopic calcification. A renal transplant was performed due to end-stage renal disease, but graft failure occurred and had to be excised due to recurrent oxalosis, again without diagnosis, despite imaging and graft biopsy. It was only when muscle calcification was noted for an unrelated indication that a diagnosis was made. The case highlights the importance of excluding all causes of nephrocalcinosis, including rare ones like oxalosis, in the management of chronic renal disease. Conclusion: We hope to alert the physician to consider primary hyperoxalosis as a differential diagnosis in renal failure patients with recurrent calcium oxalate renal stones and/or nephrocalcinosis.